The Butterfly Effect of Systemic Failure: Contaminated Cough Syrups and India’s Healthcare Crisis

 

Taste of sweetness or Taste of Death: The Cough Syrup Dilemma

In 2025, Atleast 24 lives were lost in India due to contaminated cough syrups. A paediatrician, prescribing medicine approved under the Drug and Cosmetics Act in good faith, was arrested. This doctor is not the culprit but a soft target for a deeper institutional failure to ensure drug quality. It’s like an unmanned traffic police beat where an accident occurs: the riders’ mistakes cause the crash, but the absence of a traffic policeman, whose mere presence enforces rules and reduces accidents, is an indirect cause. Similarly, the lack of robust regulatory oversight allows these tragedies to persist, eroding public trust in the system.

A Recurring Pattern and Historical Echoes

As healthcare voices on social media have noted, four such incidents have claimed lives in the last five years, with a troubling pattern among implicated manufacturers - predominantly Indian firms.

The common denominator in recent cough syrup deaths points to manufacturing lapses, such as contamination with toxic substances like Diethylene Glycol (DEG) or Ethylene Glycol (EG). The 1937 Sulfanilamide disaster in the US, where Elixir Sulfanilamide killed patients, should have been a lesson. A letter from Dr A.S. Calhoun on October 22, 1937, described the agony of losing patients to a trusted medicine turned poison.

But to realize that six human beings, all of them my patients, one of them my best friend, are dead because they took medicine that I prescribed for them innocently, and to realize that that medicine which I had used for years in such cases suddenly had become a deadly poison in its newest and most modern form, as recommended by a great and reputable pharmaceutical firm in Tennessee: well, that realization has given me such days and nights of mental and spiritual agony as I did not believe a human being could undergo and survive. I have known hours when death for me would be a welcome relief from this agony.

- Letter by Dr A.S. Calhoun, October 22, 1937

The medicine that killed Dr Calhoun's patients was Elixir Sulfanilamide. 88 Years later, history repeats in India, but the arrest of the paediatrician by the authorities is a classical example of legal illiteracy. This arrested paediatrician's mental state would have been no different from Dr A.S. Calhoun's.

The Doctor’s Dilemma and Manufacturer Accountability

By no means or mechanism can a doctor ascertain manufacturing defects like contamination. Holding the prescribing physician culpable for an undetected flaw in drug formulation shifts accountability from where it belongs to [Manufacturers and regulators]. This arrested paediatrician's mental state would have been no different from Dr A.S. Calhoun's, grappling with the unintended harm from medicines once deemed safe. Why shift blame? Politicians fear losing votes, regulators fear losing jobs, and there’s little political will or incentive to hold authorities accountable. Meanwhile, the public, distracted by reels, cricket, and reality shows, rarely demands answers.

The Burden on Taxpayers and Market Dynamics

The average Indian earns $2,500 annually, paying up to 40% of their income and expenses in taxes to fund the state, expecting a system that prioritises their welfare, including safe medicines.

Ensuring the quality of medicines produced by the Indian pharmaceutical companies through regulatory mechanisms is the sole responsibility of the state, not the doctor. The state-run healthcare facilities, funded entirely by taxpayers, rely heavily on unbranded generics due to financial constraints. Providing branded generics or innovator drugs to all in a state-run healthcare facility is unsustainable.

The Practitioner’s Plight and Public Vulnerability

A practitioner in a state-run facility has to prescribe medicines supplied by the state, which are mostly unbranded generics—yet how can they be confident when the state fails to ensure their quality? When generics fail due to lapses in quality control, doctors in private practice may lose confidence and may resort to defensive prescribing, favouring more expensive innovator brands. This inflates medical bills, hitting the common taxpayer hardest. A section of the public, bypassing doctors, directly buys prescription-only medicines from pharmacies on the advice of quacks. These patients, often unaware of the risks, are the worst off, facing dire consequences from substandard drugs.

The Policy Disconnect and Butterfly Effect

The state mandates generic prescribing to keep healthcare affordable, but its failure to ensure consistent quality undermines this policy. When trust in regulatory bodies crumbles, faith in India’s public healthcare system follows. Private practitioners, wary of legal risks, may shift to innovator brands, further driving up costs. Meanwhile, policymakers, insulated by access to private care or the ability to afford innovator drugs, remain untouched by these failures. This isn’t just a rant—it’s a call to recognise the reality. The public’s silence enables this cycle. Every choice not to question policymakers has a butterfly effect: higher costs, eroded trust, and lives lost. It’s time the taxpayers start thinking if the system, which they fund and expect to sustain them, truly serves their needs. Consider this: there’s another dimension to this crisis - institutional and regulatory failure, the hidden pressures on doctors and the untold stories of patients - that the media rarely explores.

---

📖 Read more posts at www.drsubramaniant.com [FREE ACCESS]